Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

Recruiting N/A Interventional Study
Tricuspid Regurgitation
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
236 (estimated)
Sponsor
Hangzhou Valgen Medtech Co., Ltd · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (DragonFly-T s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. In the judgment of the local cardiac team, the patient has been adequately treated according to applicable standards (including medical management)and has been stable for at least 30 days. 3. Despite the drug optimization treatment according to the above met…
Contacts

Bo Liu

+8613001980902

bo.liu@valgenmed.com

CONTACT

Shuangjie Li

+8617756106609

shuangjie.li@valgenmed.com

CONTACT